Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study - Thuluva, Subhash; Paradkar, Vikram; Gunneri, SubbaReddy; Yerroju, Vijay; Mogulla, Rammohan; Suneetha, Pothakamuri Venkata; Turaga, Kishore; Kyasani, Mahesh; Manoharan, Senthil Kumar; Adabala, Srikanth; Javvadi, Aditya Sri; Medigeshi, Guruprasad; et al. (medRxiv, 2022)
Background After establishing safety and immunogenicity of Biological E’s CORBEVAX™ vaccine in adult population (18-80 years) in Phase 1-3 studies, vaccine is further tested in children and adolescents in this study.Methods This is a phase-2/3 prospective, randomised, double-blind, placebo controlled, study evaluating safety, reactogenicity, tolerability and immunogenicity of CORBEVAX™ vaccine in children and adolescents of either gender between <18 to >=12 years of age in Phase-II and <18 to >=5 years of age in Phase-III with placebo as a control. This study has two age sub groups; age subgroup-1 with subjects <18 to >=12 years of age and age subgroup-2 with subjects <12 to >=5 years of age. In both age sub groups eligible subjects (SARS-CoV-2 RT-PCR negative and seronegative at baseline) were randomized to receive either CORBEVAX™ vaccine or Placebo in 3: 1 ratio.Findings The safety profile of CORBEVAX™ vaccine in both pediatric cohorts was comparable to the placebo control group. Majority of reported adverse events (AEs) were mild in nature. No severe or serious AEs, medically attended AEs (MAAEs) or AEs of special interest (AESI) were reported during the study period and all the reported AEs resolved without any sequelae. In both pediatric age groups, CORBEVAX™ vaccinated subjects showed significant improvement in humoral immune-responses in terms of anti-RBD-IgG concentrations, anti-RBD-IgG1 titers, neutralizing antibody (nAb)-titers against Ancestral Wuhan and Delta strains. Significantly high interferon gamma immune response (cellular) was elicited by CORBEVAX™ vaccinated subjects with minimal effect on IL-4 cytokine secretion.Interpretations The safety profile of CORBEVAX™ vaccine in <18 to >=5 years’ children and adolescents was found to be safe and tolerable. The adverse event profile was also found to be acceptable. Significant increase in anti-RBD IgG and nAb titers and IFN-gamma immune responses were observed post vaccination in both pediatric age sub groups. Both humoral and cellular immune responses were found to be non-inferior to the immune responses induced by CORBEVAX™ vaccine in adult population. This study shows that CORBEVAX™ vaccine is highly immunogenic and can be safely administered to pediatric population as young as 5 years old.The study was prospectively registered with clinical trial registry of India-CTRI/2021/10/037066Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2021/10/037066Funding StatementBIRAC- a division of the Department of Biotechnology, Govt of India provided partial funding for the execution of trials. CEPI provided support for nAb titer testing in terms of reagents. Funding sources were not involved in the study conduct, data analysis/interpretation or writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Investigational Review Board or Ethics Committee at each study site approved the protocol. All participants provided written informed consent before enrollment into the study. 1IEC-Mysore Medical College and Research Institute, Irwin Road, Mysuru 57000, Karnataka, IndiaApproved 08-10-2021ECR/134/Inst/KA/2013/RR-19 2Institutional Ethics Committee JSS Medical College, JSS Medical College and Hospital, Sri Shivarathreeshwara Nagar, Mysuru - 570015, Karnataka, India Approved 05-10-2021ECR/387/Inst/KA/2013/RR-19 3Ethics Committee Guru Teg Bahadur Hospital Dilshad Garden, Delhi - 110095 IndiaApproved 06-10-2021ECR/510/Inst/DL/2014/RR-20 4Institutional Ethics Committee, KLE University KLE University KLE Dr.PK Hospital and MRC, Nehru Nagar, Belagavi 590010 Karnataka, India. Approved 26-10-2021ECR/211/Inst/KA/2013/RR-19 5Shubham Sudbhawana Superspeciality Hospital - Ethics Committee, B 31/80, 23B - Bhogabeer, Lanka, Varanasi - 221005, Uttar Pradesh, IndiaApproved 09-10-2021ECR/667/Inst/UP/2014/RR-20 6Institutional Ethics Committee, Government Medical College and Hospital, Government Medical College Medical Square, Hanuman Nagar Nagpur 440003, Maharashtra, IndiaApproved 25-10-2021ECR/43/Inst/MH/2013/RR-19 7IEC NIMS University, Hotam administrative block, Delhi- Jaipur highway, Jaipur- 303121, Rajasthan, India. Approved 04-10-2021ECR/665/Inst/RJ/2014/RR-17 8Sant Dnyaneshwar Medical Education & Research Centre - Institutional Review Board, 695/A, Sadashiv Peth, Opp. Vijay Talkies, Laxmi Road, Pune 411030, MaharashtraApproved 27-10-2021ECR/127/Inst/MH/2013/RR-19 9ETHICS COMMITTEE, St. Theresa’s Hospital, Sanath Nagar, Opp. Erragada Raitu Bazar, Hyderabad 500018, Telangana, IndiaApproved 01-10-2021ECR/230/Inst/AP/2013/RR-19 10IEC, Mahatma Gandi Institute Of Medical Sciences, Sewagram, Wardha 442102, Maharshtra, india Approved 23-10-2021ECR/47/Inst/MH/2013/RR-19 11Ethics Committee Dy.Patil Vidyapeeth, Pimpri, Pune - 411018, Maharashtra, IndiaApproved 07-12-2021ECR/361/Inst/MH/2013/RR-19 12IRB Christian Medical college, Office of Research, 1st floor, Carman Block, Bagayam, Vellore 632002, Tamilnadu, India. Approved 30-10-2021ECR/RENEW/INST/2019/3526 13Institutional Ethics Committee for ESIC Medical College And Hospital NH-3, NIT, Behind BK Hospital, Faridabad 121001, Haryana, IndiaApproved 16-10-2021ECR/1539/Inst/HR/2021 14IEC Prakhar Hospital Pvt Ltd, 8/219, Arya Nagar, Kanpur 208002, Uttar Pradesh, India. Approved 20-10-2021ECR/1017/Inst/UP/2017/RR-21 15Aakash Healthcare Institutional Ethics Committee, Road No. 201, Sector 3, Dwarka, New Delhi - 110075, IndiaApproved 09-11-2021ECR/1265/Inst/DL/2019 16Gullurkar Hospital Ethics Committee, Plot no. 20, Reshimbag Umred Road, Nagpur- 440009, Maharashtra, IndiaApproved 18-11-2021ECR/1374/Inst/MH/2020 17Institutional Ethics Committee- Induss Hospital, 13-23-93/1, Krishnaveninagar, Gaddiannaram, Near Muncipal Office, Saroornagar, Ranga Reddy Dist., Hyderabad 500035, Telangana, IndiaApproved 06-11-2021ECR/1606/Inst/TG/2021 18Institutional Ethics Committee- Jeevan Rekha Hospital, Dr. B.R. Ambedkar Road, Opp Civil Hospital, Belagavi- 590002, Karnataka, IndiaApproved 06-11-2021ECR/1242/Inst/KA/2019 19Institutional Ethics Committee - Jawahar Lal Nehru Medical College, Kala Bagh Ajmer - 305001, Rajasthan, IndiaApproved 22-11-2021ECR/1156/Inst/RJ/2018/RR-22 20Lifepoint Research- Ethics Committee, 145/1, Mumbai-Bangalore highway, Near Hotel Sayaji, Wakad, Pune - 411057, Maharashtra, IndiaApproved 09-11-2021ECR/751/Inst/MH/2015/RR-21 21Penta-Med Ethics Committee, Medipoint Hospitals Pvt. Ltd, 241/1, New D.P.Road, Near Sai Heritage, Pune - 411007, Maharashtra, IndiaApproved 12-11-2021ECR/357/Inst/MH/2013/RR-20 22Unique Children’s Hospital Ethics Committee, Hira Moti Fortune Opp. Police station, Pune Mumbai Road, Chinchwad, Pune-411019, Maharashtra, IndiaApproved 16-12-2021ECR/1203/Inst/MH/2019 23CARE-IHEC for Faculty Research Chettinad Academy Of Research And Education, Rajiv Gandhi Salai (OMR),Kelambakkam, Kanchipuram - 603103, Tamil Nadu, IndiaApproved 09-12-2021ECR/1589/Inst/TN/2021 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAdditional study data which is not part of the manuscript can be made available upon request and addressed to the corresponding author Dr. Subhash Thuluva at his email subhash.thuluvaatbiologicale.com